Recent advances and application value of circRNA in neuroblastoma

Ke Wu; Juan Tan; Chao Yang

doi:10.3389/fonc.2023.1180300

Recent advances and application value of circRNA in neuroblastoma

Front Oncol. 2023 Apr 6:13:1180300. doi: 10.3389/fonc.2023.1180300. eCollection 2023.

Authors

Ke Wu¹, Juan Tan², Chao Yang^{2

3}

Affiliations

¹ Department of Pharmacology, Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing Medical University, Chongqing, China.
² Child Healthcare Department, Children's Hospital of Chongqing Medical University, Chongqing, China.
³ Department of Pediatric Surgical Oncology, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China.

Abstract

Neuroblastoma (NB) is children's most prevalent solid malignant tumor, accounting for 15% of childhood cancer mortality. Non-coding RNA is important in NB pathogenesis. As a newly identified non-coding RNA, abnormal regulation (abnormal up-regulation or down-regulation) of the circRNAs expression is implicated in the tumorigenesis of various tumors, including NB. CircRNAs primarily regulate the expression of microRNA (miRNA) target genes by microRNA (miRNA) sponge adsorption. Clinical evidence suggests that the expression of certain circRNAs is associated with the prognosis and clinical features of NB and hence may be exploited as a biomarker or therapeutic target. This review examines circRNAs that have been demonstrated to play a function in NB.

Keywords: biomarkers; circRNA; neuroblastoma; pathogenesis; tumor targeted therapy.

Publication types

Review